http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
엄명용,정순영,이원규 한국컴퓨터교육학회 2003 컴퓨터교육학회 논문지 Vol.6 No.4
본 논문에서는 기존의 LCMS에서 사용되는 평가시스템에 퍼지 추론 규칙을 이용한 적응형 퍼지평가시스템(AFES : Adaptie Fuzzy Evaluation System)을 제안한다. AFES 는 학습자가 하나의 학습코스(learning course)에 들어가기 전에 퍼지진단평가(fuzzy diagnostic evealuation)를 통해 학습자에게 코스수준(course level)을 부여한다. 학습자는 코스수준에 따른 맞춤식 학습경로(learning path)로 학습을 종료한 후, 퍼지최종평가(fuzzy final evaluation)를 통해 최종성적(final grade)을 AFES 으로부터 부여 받는다. AFES, 의 가장 큰 특징은 최종성적의 점수 부여 규칙에 있는데, 만약 서로 다른 학습자가 동일한 문제 수에 대하여 같은 수의 정답을 냈더라도, AFES 는 125 가지 퍼지 추론 규칙(fuzzy reasoning rule)에 의거하여 탄력적으로 서로 다른 최종성적을 학습자에게 부여한다. We introduce an AFES(Adaptive Fuzzy Evaluation System) that applies an evaluation system used to existing LCMS(Learning Contents Management System) to a fuzzy reasoning rule. The AFES confers a course level on the learner through a fuzzy diagnostic evaluation before the learner enters a learning course. After the learner completes a learning course through the tailored learning path that is suitable for the learner’s level, the AFES confers a final grade on the learner by means of fuzzy final evaluation. The biggest characteristic of the AFES is a grade rule of the final grade. Although different learners get the same number of correct answers to the same number of questions, AFES flexibiv confers the different final grade on the learner by means of the number of 125’s fuzzy reasoning rules.
( Soo Jung Um ),( Su Mi Lee ),( Soo Keol Lee ),( Choon Hee Son ),( Mee Kyung Ko ),( Mee Sook Roh ),( Ki Nam Lee ),( Pil Jo Choi ) 대한결핵 및 호흡기학회 2011 Tuberculosis and Respiratory Diseases Vol.70 No.4
Background: It is well-known that cell-free nucleic acids rise in patients with many types of malignancies. Several recent experimental studies using cancer cell lines have shown that changes in cell-free RNA are predictive of the response to chemotherapy. The objective of this study was to determine whether quantification of free RNA can be used as a biomarker for clinical responses to chemotherapy in patients with lung cancer. Methods: Thirty-two patients with lung cancer (non-small cell lung cancer, n=24; small cell lung cancer, n=8) were divided into 2 groups according to their responses to chemotherapy (response group, n=19; non-response group, n=13). Blood samples were collected before and after two cycles of chemotherapy. Real-time quantitative RT-PCR was used for transcript quantification of the glyceraldehyde-3-phosphate dehydrogenase gene. Results: The pre chemotherapy values (Response group 41.36±1.72 vs. Non-response group 41.33±1.54, p=0.78) and post chemotherapy values (Response group 39.92±1.81 vs. Non-response group 40.41±1.47, p=0.40) for cell free RNA concentrations, expressed as Ct GAPDH (threshold cycle glyceraldehyde-3-phosphate dehydrogenase gene) levels, was not different between the two groups. There was no significant relationship between changes in the cell free RNA level clinical responses after chemotherapy (p=0.43). Conclusion: We did not find a correlation between quantification of serum cell free RNA levels and clinical responses to chemotherapy in patients with lung cancer. Further investigations are needed to determine whether the cell free RNA level is a useful predictor of responses to chemotherapy in patients with lung cancer.
Um, Soo-Jung,Lee, Su-Mi,Lee, Soo-Keol,Son, Choon-Hee,Ko, Mee-Kyung,Roh, Mee-Sook,Lee, Ki-Nam,Choi, Pil-Jo The Korean Academy of Tuberculosis and Respiratory 2011 Tuberculosis and Respiratory Diseases Vol.70 No.4
Background: It is well-known that cell-free nucleic acids rise in patients with many types of malignancies. Several recent experimental studies using cancer cell lines have shown that changes in cell-free RNA are predictive of the response to chemotherapy. The objective of this study was to determine whether quantification of free RNA can be used as a biomarker for clinical responses to chemotherapy in patients with lung cancer. Methods: Thirty-two patients with lung cancer (non-small cell lung cancer, n=24; small cell lung cancer, n=8) were divided into 2 groups according to their responses to chemotherapy (response group, n=19; non-response group, n=13). Blood samples were collected before and after two cycles of chemotherapy. Real-time quantitative RT-PCR was used for transcript quantification of the glyceraldehyde-3-phosphate dehydrogenase gene. Results: The pre chemotherapy values (Response group $41.36{\pm}1.72$ vs. Non-response group $41.33{\pm}1.54$, p=0.78) and post chemotherapy values (Response group $39.92{\pm}1.81$ vs. Non-response group $40.41{\pm}1.47$, p=0.40) for cell free RNA concentrations, expressed as Ct GAPDH (threshold cycle glyceraldehyde-3-phosphate dehydrogenase gene) levels, was not different between the two groups. There was no significant relationship between changes in the cell free RNA level clinical responses after chemotherapy (p=0.43). Conclusion: We did not find a correlation between quantification of serum cell free RNA levels and clinical responses to chemotherapy in patients with lung cancer. Further investigations are needed to determine whether the cell free RNA level is a useful predictor of responses to chemotherapy in patients with lung cancer.
( Soo Jung Um ),( Bo Hyung Kang ),( Choon Hee Son ) 대한내과학회 2014 대한내과학회 추계학술대회 Vol.2014 No.1
Background: The neutrophil-lymphocyte count ratio (NLR) is an emerging infiammatory marker. Recently, several studies have demonstrated its predictive power in several infectious diseases. We herein sought to the prognostic value of serial NLR measurement in patients with community acquired pneumonia. Methods: A total of 177 patients with suspected lower respiratory infections who were admitted to the emergency department of the Dong-A university hospital were enrolled. Serum samples for NLR were collected at admission and at hospital day 4. The NLR was defined as the absolute neutrophil count divided by the absolute lymphocyte count. Results: The NLR at day 4 provided moderate prediction of clinical stability at day 4 (AUC: 0.749, 95% CI: 0.668 to 0.831, p <0.001) and mortality (AUC: 0.740, 95% CI: 0.615 to 0.865, p =0.001), whereas the NLR at admission did not show significant predictive value. A decrease in NLR between admission and day 4 was present in 84.1% (111 of 132) of patients who were stabilized at hospital day 4 and in 51.1% (22 of 45) of patients who were not stabilized (p <0.001). An increase in NLR occurred more frequently in patients who died of pneumonia than patients who recovered (58.8% vs. 20.9%, p = 0.002). A change in NLR was found to be significant and independent predictor of clinical stability at hospital day 4 (OR: 4.88, 95% CI: 2.27 to 10.52, p <0.001) and mortality (OR: 4.01, 95% CI: 1.39 to 12.03, p = 0.10) after adjusting for age, comorbid illness. Conclusions: The NLR, especially a change of measurements, was a useful laboratory marker to predict clinical stability and mortality in patients with community acquired pneumonia.
( Soo Jung Um ),( Bohyung Kang ),( Choon Hee Son ) 대한결핵 및 호흡기학회 2014 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.118 No.-
Background: The neutrophil-lymphocyte count ratio (NLR) is an emerging inflammatory marker. Recently, several studies have demonstrated its predictive power in several infectious diseases. We herein sought to the prognostic value of serial NLR measurement in patients with community acquired pneumonia. Methods: A total of 177 patients with suspected lower respiratory infections who were admitted to the emergency department of the Dong-A university hospital were enrolled. Serum samples for NLR were collected at admission and at hospital day 4. The NLR was defined as the absolute neutrophil count divided by the absolute lymphocyte count. Results: The NLR at day 4 provided moderate prediction of clinical stability at day 4 (AUC: 0.749, 95% CI: 0.668 to 0.831, p <0.001) and mortality (AUC: 0.740, 95% CI: 0.615 to 0.865, p =0.001), whereas the NLR at admission did not show significant predictive value. A decrease in NLR between admission and day 4 was present in 84.1% (111 of 132) of patients who were stabilized at hospital day 4 and in 51.1% (22 of 45) of patients who were not stabilized (p <0.001). An increase in NLR occurred more frequently in patients who died of pneumonia than patients who recovered (58.8% vs. 20.9%, p = 0.002). A change in NLR was found to be significant and independent predictor of clinical stability at hospital day 4 (OR: 4.88, 95% CI: 2.27 to 10.52, p <0.001) and mortality (OR: 4.01, 95% CI: 1.39 to 12.03, p = 0.10) after adjusting for age, comorbid illness. Conclusions: The NLR, especially a change of measurements, was a useful laboratory marker to predict clinical stability and mortality in patients with community acquired pneumonia.